



Fluxion – Measuring organoid metabolism in real time

Fluxion

THE PROBLEM

Drug-induced liver injury (DILI) remains a major cause of drug failure, yet advanced liver models are still assessed largely through endpoint measurements. Early metabolic dysfunction and differences between individual organoids can remain hidden.

OUR SOLUTION

Fluxion is a hardware platform enabling real-time metabolic measurements in individual liver organoids and advanced cell models. It reveals dynamic drug responses and organoid-to-organoid variability that bulk endpoint measurements can miss.

PATENT STATUS

PCT patent application filed (August 2025).

FINANCIAL OVERVIEW

Fluxion is developed as a hardware-plus-consumables platform, combining instrument sales with recurring microfluidic chips and future data analytics.

MILESTONES

Functional research prototype completed; LOI from Stanford University; 500 kSEK investment offer secured; initial organoid collaborations established; presented at two DeepTech Summits.

Next 12 months: DILI benchmarking; industrial beta prototype; pilot customers; company formation; seed financing.

TARGET MARKET & CUSTOMERS

Initial wedge: Pharmaceutical safety teams, CROs, translational toxicology groups, and organoid-based drug testing platforms evaluating DILI.

Expansion: Drug discovery, oncology, precision medicine, and other applications where real-time metabolic readouts in individual cells or organoids improve decisions.

CO-FOUNDER PROFILE WE ARE LOOKING FOR

Preferred qualifications

Commercial: experience in life-science tools, fundraising, customer discovery, or industry partnerships.

Technical: experience in microfluidics, instrumentation, product engineering, or prototyping, with the ability to turn research technology into a robust product.

Personal fit

You want to build, not just advise. You take ownership, work hands-on, and are comfortable shaping an early-stage technology and company under uncertainty.

TASKS & RESPONSIBILITIES (FIRST 3 MONTHS)

Depending on profile: drive prototype and product development, or lead customer validation, positioning, partnerships, and fundraising. Work closely with the founders toward DILI benchmarking, pilot customers, and company formation.


Primary objective: Advance the platform toward DILI validation, beta development, pilot customers, and financing.

ACADEMIC & ENTREPRENEURIAL BACKGROUND OF CURRENT CO-FOUNDERS

Three academic co-founders combining microfluidic engineering, metabolic systems biology, and translational research at DTU. Research prototype established, IP filed, with early customer and collaboration interest. Pre-spinout stage.

PHYSICAL ADDRESS

DTU Bioengineering
Technical University of Denmark
2800 Kgs. Lyngby, Denmark



FLUXION

ABOUT OPEN ENTREPRENEURSHIP

Open Entrepreneurship is a collaboration between all Danish universities aiming to create more research-based startups.

www.open-entrepreneurship.com